Efficacy and Tolerability of Erenumab in Patients With Trigeminal Neuralgia
Status:
Unknown status
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
A placebo-controlled, double-blind, randomized proof-of-concept study to evaluate the
efficacy and tolerability of the CGRP receptor antibody erenumab in treating pain experienced
by subjects with TN.